Investigators designed a dual subunit mRNA replacement approach and packaged both Hadha and Hadhb transcripts in lipid nanoparticles for systemic delivery. The study team reported that intravenous administration of the LNP‑mRNA construct restored hepatic expression of the mitochondrial trifunctional protein complex in a moderate‑severity mouse model of hepatic‑onset trifunctional protein deficiency. The abstract states restored hepatic TFP expression was accompanied by biochemical improvements; specific dosing schedules, vector composition details, and duration of expression were not reported in the abstract and appear in the full manuscript or supplementary files. This work was presented as a preprint and has not been certified by peer review.
In vitro experiments used TFP‑D mouse fibroblasts derived from the disease model. Dual mRNA delivery rescued long‑chain fatty acid oxidation in those cells, while single‑subunit replacement did not. The authors observed a dominant negative effect exerted by an endogenous M404K variant of Hadhb, which prevented functional restoration when only one subunit was replaced. Data indicated that co‑expression of both subunits is necessary to reconstitute enzymatic activity in patient‑derived or disease‑model cells where a pathogenic subunit allele interferes with complex assembly or function. The abstract does not provide raw enzyme activity values, timepoints, or transfection efficiencies; readers should consult the full text for experimental methods and quantitative results.
After systemic intravenous delivery, the investigators reported reductions in circulating long‑chain acylcarnitines in treated mice. Circulating acylcarnitines are standard biochemical markers used to assess long‑chain fatty acid oxidation dysfunction. In this model, lowering those metabolites paralleled restoration of hepatic TFP expression. The abstract makes clear that the biochemical signal moved toward normalization following dual Hadha/Hadhb mRNA treatment, but it did not include numerical fold‑changes, baseline values, or timecourse details in the summary. Those precise biomarker data are contained in the full report and supplementary material rather than in the abstract alone.
The treatment yielded measurable physiological benefit in aged TFP‑D animals. Investigators reported significant rescue of cold tolerance test (CTT) performance after intravenous dual mRNA‑LNP administration, with improvement up to 71.6% compared to untreated and healthy controls. The study team also described overall improved physiological performance in treated mice, linking biochemical correction to functional outcomes. The abstract does not list additional functional assays, survival data, or potential effects on other organs; these endpoints likely appear in the main manuscript. The observed CTT improvement provides a functional readout relevant to the energy‑deficit phenotype characteristic of TFP‑D.
The authors propose that dual subunit LNP‑mRNA replacement could be applicable to other long‑chain fatty acid oxidation disorders. The preprint notes potential broader relevance but does not present clinical trial plans or human safety data. Key unanswered questions remain in the abstract: long‑term durability of hepatic expression, repeat‑dose tolerability, immunogenicity of the delivered mRNAs or LNPs, and comprehensive toxicology were not reported there. The work was funded in part by the National Institute of General Medical Sciences and Duke University. Competing interests disclosed include provisional patents filed by some authors and a company affiliation for one listed investigator.
Limitations stated or implicit in the source: the study is reported as a preprint and has not undergone peer review; experiments were performed in a mouse model and in cultured fibroblasts, so translatability to humans is not established within the abstract; detailed dosing, safety, and long‑term outcome data are not described in the abstract and must be reviewed in the full publication and supplementary materials for thorough assessment.